Although one injection of lv-Fendrr did not cause obvious liver fibrosis (data not shown), hepatic α-SMA, the representative marker of HSC activation, was greatly upregulated, suggesting that the increase of Fendrr is implicated with HSC activation, most likely by inducing IL-6 (Fig. 5, H and I). Here, IL6 is linked to Hepatic fibrosis.